🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

👀

Thoroughly enjoyed the JSMO-RISA workshop yesterday. Great lectures, learnt a lot, networked across Asia, made new friends and future collaborators! Loving #Kobe so far. 🇯🇵 Thank you 日本臨床腫瘍学会（JSMO） #JSMO25

Spent the early evening here at the conference listening to Prof G Curigliano MD PhD speak on sequencing ADCs in mTNBC. Beautiful venue #JSMO25 #Kobe 日本臨床腫瘍学会（JSMO） 🇯🇵

Spent the day supporting new friends at their oral presentations and they in turn attending mine! 🇸🇬🇦🇺🇲🇾🇯🇵 #JSMO25 日本臨床腫瘍学会（JSMO） Thanks to David D. W. Lee, MBBS, FRCR. for being our highly qualified photographer.

Certainly did not expect this! Awarded the Best Rising Star Award at #JSMO25. Thank you 日本臨床腫瘍学会（JSMO）! 🤩

📢 #ESMOFellowship applications are now open! The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch or #ClinicalResearch projects. 📅 Apply by: 29 May 2025 🔗 ow.ly/tz3e50VAQuM Evandro de Azambuja, MD, PhD Teresa Amaral, MD, PhD

An excellent review on a topic that comes up so frequently in clinic. Nicely done, (Elisa Agostinetto) and team!

It’s already time! #ESMOAsia25

Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials - Journal of Hepatology journal-of-hepatology.eu/article/S0168-…

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm 🔗 ow.ly/VtAE50VP4Jf

I certainly want to see the results from ROSELLA and the ctDNA data from the. Durva/olaparib/chemo study!

Having #ASCO25 FOMO!! Hoping to go next year for my first ever ASCO / trip to Chicago 🥰 🇦🇺 | ✈️ | 🇺🇸 I’ve taken tips from Narjust Florez, MD, FASCO about what to plan/pack, and Rachna Shroff, MD, MS, FASCO about packing only in a carry on (incl 6 pairs of shoes)! What else do I need to know?

Dr. Tie presents Phase 2 #coloncancer and #ctDNA based on Dynamic-III for stage 3 pts for a primary endpoint of 2-RFS (goal HR < .746) demonstrates if ctDNA+ 🛑 No statistical diff for dose escalation. #cancer #canceresearch #clinicaltrials

Fantastic discussion by #BrianWolpin on #PDAC studies at #ASCO25 Further details on each one coming soon 😉 ASCO Grupo Español de Tratamiento de Tumores Digestivos SEOM

#Honoured and #humbled to have been awarded #FASCO and #ASCO25. My thanks to my friends and colleagues for your overwhelming support along the way 😊 #sarcoma #LCSM #InternationalAffairsCommittee #drugdevelopment #precisiononcology

No comments needed 🤩🥳😍 congrats super Sara Tolaney from Dana-Farber and all involved in the #DB09 trial !!!! #ASCO25 OncoAlert ASCO Dana-Farber’s Breast Oncology Center

Bottom line from the #ctDNA analyses in CALLA study in #CervicalCancer (addition of durva to chemoradiation) 👀 Low ctDNA both at baseline and after completion of chemoXRT associated with better survival 🤔 ctDNA status was most significant prognostic factor #ASCO25 #gyncsm

Dear WeRateDogs Haddon <checks nametag> The Dog is currently raising spirits at the largest cancer conference in the world #ASCO25, 14/10, did boop

Really proud for @ANZGOG and #APGOT to have been involved with this practice changing study for women with platinum resistant ovarian cancer! Peter Mac Cancer Centre

Great opportunity for healthcare professionals to hear from ANZGOG co-founder Prof Michael Friedlander AM and a panel of experts as they present key #gynaecologicalcancer highlights from #ASCO25 and discuss what they mean for patient care in Australia. the limbic